S 4987 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Pharmaceutical Investment Oversight and Accountability Act
To require the Federal Trade Commission to submit a report on foreign investment in the pharmaceutical industry of the United States, and for other purposes.
Summary
- Requires the Federal Trade Commission to submit annual reports to Congress and federal health agencies on foreign investment in the U.S. pharmaceutical industry.
- Reports must assess the pharmaceutical supply chain, effects of foreign investment on domestic drug manufacturing capacity, and foreign investment in DNA sequencing and storage technologies.
- Reports must document all foreign investment reviews and investigations conducted over the prior ten fiscal years for pharmaceutical and DNA-related transactions.
- Requires the FTC to publish an unclassified summary of each report on a public website.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
2 cosponsors
Actions (2)
- Jul 15, 2026 Read twice and referred to the Committee on Banking, Housing, and Urban Affairs. · senate
- Jul 15, 2026 Introduced in Senate
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Full text
IN THE SENATE OF THE UNITED STATES
July 15, 2026
Ms. Warren (for herself, Mr. Scott of Florida, and Mrs. Gillibrand) introduced the following bill; which was read twice and referred to the Committee on Banking, Housing, and Urban Affairs
A BILL
To require the Federal Trade Commission to submit a report on foreign investment in the pharmaceutical industry of the United States, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Pharmaceutical Investment Oversight and Accountability Act”.
SEC. 2. OVERSIGHT OF FOREIGN PHARMACEUTICAL INVESTMENT.
(a) In General.—Not later than 1 year after the date of the enactment of this Act, and annually thereafter, the Federal Trade Commission, in consultation with the Secretary of the Treasury acting through the Committee on Foreign Investment in the United States (referred to in this section as the “Committee”), shall submit to the appropriate congressional committees, the Secretary of Health and Human Services, and the Commissioner of Food and Drugs, a report on foreign investment in the pharmaceutical industry of the United States.
(b) Elements.—The report required by subsection (a) shall include the following:
(1) An assessment of—
(A) the supply chain of the pharmaceutical industry of the United States and the effect of concentration and reliance on foreign manufacturing within that industry;
(B) the effect of foreign investment in the pharmaceutical industry of the United States on domestic capacity to produce drugs (as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(g))) and active and inactive ingredients of drugs; and
(C) the effect of foreign investment in technologies or other products for sequencing or storage of DNA, including genome and exome analysis, in the United States, including the effect of such investment on the capacity to sequence or store DNA in the United States.
(2) The number of reviews and investigations conducted by the Committee, in each of the 10 fiscal years preceding the year in which the study is conducted, with respect to covered transactions (as defined in section 721(a) of the Defense Production Act of 1950 (50 U.S.C. 4565(a)))—
(A) in pharmaceutical and medicine manufacturing in the United States; or
(B) relating to the sequencing or storage of DNA in the United States.
(3) A short description of each such review or investigation, including whether the transaction was approved or prohibited and any approvals subject to mitigation agreements.
(c) Authority.—The Federal Trade Commission shall have authority under section 6 of the Federal Trade Commission Act (15 U.S.C. 46) to conduct the studies required to prepare the report required by subsection (a).
(d) Publication.—The Federal Trade Commission shall publish an unclassified summary of the report required by subsection (a) on a publicly available internet website of the Commission.
(e) Appropriate Congressional Committees Defined.—In this section, the term “appropriate congressional committees” means—
(1) the Committee on Banking, Housing, and Urban Affairs, the Committee on Health, Education, Labor, and Pensions, the Committee on Armed Services, the Committee on Foreign Relations, the Committee on Commerce, Science, and Transportation, and the Committee on Appropriations of the Senate; and
(2) the Committee on Financial Services, the Committee on Energy and Commerce, the Committee on Armed Services, the Committee on Foreign Affairs, and the Committee on Appropriations of the House of Representatives. <all>
Comments